Wanbury Ltd

Wanbury Ltd

Wanbury Ltd has received awards for its Tanuku and Patalganga facilities for employee practices and safety performance, including a 'Best Employer' award from the State Government of Andhra Pradesh and a 'Certificate of Excellence' from the National Safety Council.

Wanbury Ltd

Wanbury Ltd has received 9 'No DMF Deficiency' letters from USFDA for Metformin HCl, expanding its Metformin business in Saudi Arabia and Mexico, and validating new APIs such as Quetiapine Fumarate, Sitagliptin, and Empagliflozin. The company has also commercialized a new Metformin DC business in Saudi Arabia with an annual revenue potential of about Rs 10 crore and won a two-year tender for the supply of Metformin in Mexico valued at approximately Rs 15 crore per annum.

Wanbury Ltd

Wanbury Ltd's subsidiary Wanbury Skin Health Limited has launched its berrysoft baby product range across multiple states in India, marking a strategic entry in the Paediatric Dermatology segment.

Wanbury Ltd

Wanbury Ltd's subsidiary Wanbury Skin Health Limited has launched its berrysoftTM baby product range across multiple states in India, marking a strategic entry in the Paediatric Dermatology segment.

Wanbury Ltd

Wanbury Ltd has submitted a certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities for the quarter ended September 2026.

Wanbury Ltd

Wanbury Ltd has filed a new Drug Master File (DMF) in South Africa for Tramadol HCl API, and also filed DMFs in Philippines and Singapore for Metformin HCl API, and added new Key Starting Materials (KSM) vendors for its CEP filed API, Paroxetine HCl.

Wanbury Ltd

Wanbury Ltd has announced the closure of its trading window for dealing in securities from 1st October, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended 30th September, 2026.

Wanbury Ltd

Wanbury Ltd announced the voting results and scrutinizer report of its 38th Annual General Meeting (AGM) held on September 24, 2026. The meeting saw a total of 349,669,028 votes cast, with all resolutions being passed. The company's financial statements for the year ended March 31, 2026, were also approved. The meeting was attended by 2 promoters and 100 public shareholders through video conferencing.

Wanbury Ltd

Wanbury Ltd has announced the re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director beyond the age of 70, and the appointment and ratification of remuneration payable to M/s. ABK & Associates, Cost Accountant, for conducting cost audit for the Financial Year 2026-2027.

WANBURY LIMITED

WANBURY LIMITED has informed BSE about the appointment of Cost Auditors - XBRL.

WANBURY LIMITED

Wanbury Limited has informed BSE about the appointment of Cost Auditors - XBRL.

WANBURY LIMITED

Wanbury Limited has informed BSE about the re-appointment of an Executive Director.

WANBURY LIMITED

Wanbury Limited has informed BSE about the appointment of Cost Auditors - XBRL.

WANBURY LIMITED

Wanbury Limited has informed BSE about the appointment of Cost Auditors - XBRL.

WANBURY LIMITED

Wanbury Limited has informed BSE about the re-appointment of an Executive Director.

WANBURY LIMITED

Wanbury Limited has informed BSE about the re-appointment of an Executive Director.

WANBURY LIMITED

Wanbury Limited has informed BSE about the appointment of Cost Auditors - XBRL.

WANBURY LIMITED

Wanbury Limited has informed BSE about the appointment of Cost Auditors - XBRL.

WANBURY LIMITED

Wanbury Limited has informed BSE about the re-appointment of an Executive Director.

WANBURY LIMITED

Wanbury Limited has informed BSE about the re-appointment of an Executive Director.